ATE232722T1 - Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung - Google Patents

Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung

Info

Publication number: ATE232722T1
Authority: AT; Austria
Prior art keywords: cyclosporin; lactide; poly; nanospheres; formulation
Prior art date: 1995-04-03

Application number

AT96909319T

Other languages

English (en)

Inventor

Zebunnissa Ramtoola

Original Assignee

Elan Corp Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-03

Filing date

1996-04-02

Publication date

2003-03-15

1996-04-02 Application filed by Elan Corp Plc filed Critical Elan Corp Plc

2003-03-15 Application granted granted Critical

2003-03-15 Publication of ATE232722T1 publication Critical patent/ATE232722T1/de

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 6
229930105110 Cyclosporin A Natural products 0.000 title abstract 6
108010036949 Cyclosporine Proteins 0.000 title abstract 6
229960001265 ciclosporin Drugs 0.000 title abstract 6
229930182912 cyclosporin Natural products 0.000 title abstract 6
239000002077 nanosphere Substances 0.000 title abstract 5
238000013270 controlled release Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 abstract 5
239000004005 microsphere Substances 0.000 abstract 4
JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 abstract 3
229920002988 biodegradable polymer Polymers 0.000 abstract 3
239000004621 biodegradable polymer Substances 0.000 abstract 3
238000009472 formulation Methods 0.000 abstract 3
239000002702 enteric coating Substances 0.000 abstract 1
238000009505 enteric coating Methods 0.000 abstract 1
239000006186 oral dosage form Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229920000747 poly(lactic acid) Polymers 0.000 abstract 1
229940065514 poly(lactide) Drugs 0.000 abstract 1
-1 poly(lactide) Polymers 0.000 abstract 1
210000000813 small intestine Anatomy 0.000 abstract 1
210000002784 stomach Anatomy 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/795—Composed of biological material
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/931—Medical device coating

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)

AT96909319T 1995-04-03 1996-04-02 Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung ATE232722T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IE950233A IE75744B1 (en)	1995-04-03	1995-04-03	Controlled release biodegradable micro- and nanospheres containing cyclosporin
PCT/IE1996/000017 WO1996031202A1 (en)	1995-04-03	1996-04-02	Controlled release biodegradable micro- and nanospheres containing cyclosporin

Publications (1)

Publication Number	Publication Date
ATE232722T1 true ATE232722T1 (de)	2003-03-15

Family

ID=11040700

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96909319T ATE232722T1 (de)	1995-04-03	1996-04-02	Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung

Country Status (14)

Country	Link
US (1)	US5641745A (de)
EP (1)	EP0818996B1 (de)
JP (1)	JP3875721B2 (de)
AT (1)	ATE232722T1 (de)
AU (1)	AU700612B2 (de)
CA (1)	CA2217462C (de)
DE (1)	DE69626278T2 (de)
DK (1)	DK0818996T3 (de)
ES (1)	ES2189868T3 (de)
IE (1)	IE75744B1 (de)
NZ (1)	NZ304975A (de)
PT (1)	PT818996E (de)
WO (1)	WO1996031202A1 (de)
ZA (1)	ZA962670B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6090925A (en)	1993-03-09	2000-07-18	Epic Therapeutics, Inc.	Macromolecular microparticles and methods of production and use
US5981719A (en)	1993-03-09	1999-11-09	Epic Therapeutics, Inc.	Macromolecular microparticles and methods of production and use
DE19732903A1 (de)	1997-07-30	1999-02-04	Falk Pharma Gmbh	Pellet-Formulierung zur Behandlung des Intestinaltraktes
JP4272811B2 (ja) *	1997-09-05	2009-06-03	マルホ株式会社	関節内疾患治療用のナノカプセル製剤
NZ328751A (en) *	1997-09-16	1999-01-28	Bernard Charles Sherman	Solid medicament containing an anionic surfactant and cyclosporin
JP2001517625A (ja) *	1997-09-25	2001-10-09	バイエル・アクチエンゲゼルシヤフト	活性成分放出制御薬物製剤
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
US6673768B1 (en)	1997-10-16	2004-01-06	Board Of Regents, The University Of Texas System	Transgenic animal models for cardiac hypertrophy and methods of use thereof (treating)
DE19821951A1 (de) *	1998-05-15	1999-11-18	Basf Ag	Cyclosporin-Zubereitungen
US20050085498A1 (en) *	1998-05-28	2005-04-21	Byrd Edward A.	Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6197340B1 (en) *	1998-05-28	2001-03-06	Medical Research Institute	Controlled release lipoic acid
US20040259895A1 (en) *	1998-05-28	2004-12-23	Medical Research Institute	Oral formulation of lipid soluble thiamine and lipoic acid
US6905707B2 (en) *	1998-05-28	2005-06-14	Medical Research Institute	Controlled release arginine alpha ketoglutarate
US6984404B1 (en)	1998-11-18	2006-01-10	University Of Florida Research Foundation, Inc.	Methods for preparing coated drug particles and pharmaceutical formulations thereof
ATE404172T1 (de)	1998-12-30	2008-08-15	Dexcel Ltd	Dispergierbares konzentrat zur verabreichung von cyclosporin
US6253463B1 (en)	1999-04-26	2001-07-03	Niro A/S	Method of spray drying
US6406745B1 (en)	1999-06-07	2002-06-18	Nanosphere, Inc.	Methods for coating particles and particles produced thereby
GB2381453A (en) *	1999-08-31	2003-05-07	Bradford Particle Design Ltd	Active/polymer coformulations
GB9920558D0 (en) *	1999-08-31	1999-11-03	Bradford Particle Design Ltd	Methods for particle formation and their products
US6656504B1 (en) *	1999-09-09	2003-12-02	Elan Pharma International Ltd.	Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6682754B2 (en)	1999-11-24	2004-01-27	Willmar Poultry Company, Inc.	Ovo delivery of an immunogen containing implant
US7732404B2 (en) *	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
US6565888B1 (en) *	2000-08-23	2003-05-20	Alkermes Controlled Therapeutics, Inc.	Methods and compositions for the targeted delivery of biologically active agents
US7037528B2 (en) *	2000-12-22	2006-05-02	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) *	2000-12-22	2005-04-26	Baxter International Inc.	Method for preparing submicron particle suspensions
US6977085B2 (en) *	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US20040022862A1 (en) *	2000-12-22	2004-02-05	Kipp James E.	Method for preparing small particles
US20040256749A1 (en) *	2000-12-22	2004-12-23	Mahesh Chaubal	Process for production of essentially solvent-free small particles
US9700866B2 (en) *	2000-12-22	2017-07-11	Baxter International Inc.	Surfactant systems for delivery of organic compounds
US20030072807A1 (en) *	2000-12-22	2003-04-17	Wong Joseph Chung-Tak	Solid particulate antifungal compositions for pharmaceutical use
US8067032B2 (en) *	2000-12-22	2011-11-29	Baxter International Inc.	Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) *	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7193084B2 (en)	2000-12-22	2007-03-20	Baxter International Inc.	Polymorphic form of itraconazole
US6951656B2 (en) *	2000-12-22	2005-10-04	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
AR033711A1 (es) *	2001-05-09	2004-01-07	Novartis Ag	Composiciones farmaceuticas
BR0212833A (pt)	2001-09-26	2004-10-13	Baxter Int	Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en) *	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04003625A (es)	2001-10-19	2004-12-02	Sotechnika Inc	Sintesis de analogos de ciclosporina.
IL160761A0 (en) *	2001-10-19	2004-08-31	Isotechnika Inc	Novel cyclosporin analog microemulsion preconcentrates
US7112340B2 (en)	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
KR20030065831A (ko) *	2002-02-01	2003-08-09	주식회사 태평양	사이클로스포린을 함유한 지속 방출형 약학적 조성물
KR20040098023A (ko) *	2002-03-26	2004-11-18	테바 파마슈티컬 인더스트리즈 리미티드	약물 미세입자
LT1576138T (lt)	2002-11-15	2017-06-26	Idenix Pharmaceuticals Llc	2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
US20040150061A1 (en) *	2003-01-30	2004-08-05	Hsin Chung Hsien	Package structure of a photosensor
US7507823B2 (en)	2004-05-06	2009-03-24	Bristol-Myers Squibb Company	Process of making aripiprazole particles
GB0413730D0 (en) *	2004-06-18	2004-07-21	Tillotts Pharma Ag	A pharmaceutical composition and its use
GB0413729D0 (en) *	2004-06-18	2004-07-21	Tillotts Pharma Ag	A pharmaceutical composition and its use
WO2006004774A2 (en) *	2004-06-28	2006-01-12	Stanford University	Laulimalide analogues as therapeutic agents
KR20070100836A (ko) *	2005-02-03	2007-10-11	신벤션 아게	졸/겔 기술에 의하여 제조된 약물 전달 물질
CN1323096C (zh) *	2005-05-26	2007-06-27	中国科学院长春应用化学研究所	生物可降解聚酯微粒及其制备方法和用途
WO2006138202A2 (en) *	2005-06-14	2006-12-28	Baxter International Inc.	Pharmaceutical formulations for minimizing drug-drug interactions
US20060280787A1 (en) *	2005-06-14	2006-12-14	Baxter International Inc.	Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20070134341A1 (en) *	2005-11-15	2007-06-14	Kipp James E	Compositions of lipoxygenase inhibitors
US20070298067A1 (en) *	2006-06-22	2007-12-27	Boston Scientific Scimed, Inc.	Control release drug coating for medical devices
US7794495B2 (en) *	2006-07-17	2010-09-14	Advanced Cardiovascular Systems, Inc.	Controlled degradation of stents
US8722736B2 (en)	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en)	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
EP2200613B1 (de)	2007-09-21	2018-09-05	The Johns Hopkins University	Phenazin-derivate und ihre verwendungen
US9994585B2 (en)	2007-12-31	2018-06-12	Aphios Corporation	Transplantation therapies
US20170065533A1 (en) *	2011-01-24	2017-03-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Nanoparticles for dermal and systemic delivery of drugs
US10624847B2 (en) *	2011-08-02	2020-04-21	AnPac BioMedical Science Co., Ltd.	Decomposable apparatus and methods for fabricating same
ES3018133T3 (en)	2011-11-30	2025-05-14	Univ Emory	Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
US9034347B2 (en) *	2011-12-19	2015-05-19	Arphios Corporation	Drug delivery system and method for the treatment of neuro-degenerative disease
CN105228614A (zh)	2012-11-28	2016-01-06	阿菲欧斯公司	用于治疗神经退化疾病和其它疾病的组合治疗剂和方法
WO2015138919A1 (en)	2014-03-14	2015-09-17	The University Of North Carolina At Chapel Hill	Small molecules for inhibiting male fertility
GB201522441D0 (en) *	2015-12-18	2016-02-03	Midatech Pharma Wales Ltd	Sustained release cyclosporine-loaded microparticles
KR102469342B1 (ko) *	2021-06-14	2022-11-21	주식회사 오리엔트바이오	환형 펩타이드를 포함하는 방출조절형 국소주사용 조성물 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1311686C (en) *	1986-06-25	1992-12-22	John Weldon Shell	Controlled release bioerodible drug delivery system
KR920003601B1 (ko) *	1987-09-03	1992-05-04	유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드	점안 싸이클로스포린(cyclosporin)의 조성물
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
US5185152A (en) *	1990-01-10	1993-02-09	Peyman Gholam A	Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
WO1991016057A1 (en) *	1990-04-18	1991-10-31	University Of Utah	COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING pH-DEPENDENT SWELLING
US5171217A (en) *	1991-02-28	1992-12-15	Indiana University Foundation	Method for delivery of smooth muscle cell inhibitors
CA2121038C (en) *	1992-08-13	2002-05-14	Akiya Yamada	Oral preparation for release in lower digestive tracts

1995
- 1995-04-03 IE IE950233A patent/IE75744B1/en not_active IP Right Cessation
- 1995-06-07 US US08/479,509 patent/US5641745A/en not_active Expired - Lifetime
1996
- 1996-04-02 AU AU52866/96A patent/AU700612B2/en not_active Ceased
- 1996-04-02 PT PT96909319T patent/PT818996E/pt unknown
- 1996-04-02 DK DK96909319T patent/DK0818996T3/da active
- 1996-04-02 WO PCT/IE1996/000017 patent/WO1996031202A1/en not_active Ceased
- 1996-04-02 CA CA2217462A patent/CA2217462C/en not_active Expired - Fee Related
- 1996-04-02 DE DE69626278T patent/DE69626278T2/de not_active Expired - Lifetime
- 1996-04-02 NZ NZ304975A patent/NZ304975A/en not_active IP Right Cessation
- 1996-04-02 JP JP53015696A patent/JP3875721B2/ja not_active Expired - Fee Related
- 1996-04-02 EP EP96909319A patent/EP0818996B1/de not_active Expired - Lifetime
- 1996-04-02 ES ES96909319T patent/ES2189868T3/es not_active Expired - Lifetime
- 1996-04-02 AT AT96909319T patent/ATE232722T1/de active
- 1996-04-03 ZA ZA962670A patent/ZA962670B/xx unknown

Also Published As

Publication number	Publication date
US5641745A (en)	1997-06-24
DE69626278D1 (de)	2003-03-27
CA2217462A1 (en)	1996-10-10
ES2189868T3 (es)	2003-07-16
DE69626278T2 (de)	2003-07-24
AU700612B2 (en)	1999-01-07
JP3875721B2 (ja)	2007-01-31
EP0818996B1 (de)	2003-02-19
WO1996031202A1 (en)	1996-10-10
AU5286696A (en)	1996-10-23
CA2217462C (en)	2010-08-03
PT818996E (pt)	2003-06-30
EP0818996A1 (de)	1998-01-21
IE75744B1 (en)	1997-09-24
DK0818996T3 (da)	2003-06-10
IE950233A1 (en)	1996-10-16
ZA962670B (en)	1996-10-09
NZ304975A (en)	1998-09-24
JPH11503147A (ja)	1999-03-23

Legal Events

Date

Code

Title

Description

2003-07-15

UEP

Publication of translation of european patent specification

Ref document number: 0818996

Country of ref document: EP

2010-07-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
ATE232722T1 (de)	2003-03-15	Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung
BG102438A (en)	1999-01-29	Medicamentous form
BR9810124A (pt)	2000-08-08	Um itraconazol exibindo solibilidade incrementada, o método de preparação do mesmo e a composição farmacêutica para administração oral contendo o mesmo
CY1105908T1 (el)	2011-02-02	Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
WO1997013502A3 (en)	1997-10-02	Prolonged release of gm-csf
WO1998009597A3 (en)	2001-06-28	Cushioning beads and tablet comprising the same capable of forming a suspension
IL111647A (en)	1999-12-22	Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
EP1120109A3 (de)	2002-07-10	Feste schnell zerfallende und sich auflösende Dosierungsformen
CA2285266A1 (en)	1998-10-22	Extended release formulations of erythromycin derivatives
HUP0203451A2 (hu)	2003-02-28	Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
NO975872D0 (no)	1997-12-12	Formuleringer for kontrollert frigjöring av lite opplöselige medikamenter
BG104620A (en)	2001-04-30	Oral pharmaceutical extended release dosage form
DE69631824D1 (de)	2004-04-15	Biologisch abbaubare nanopartikel mit kontrollierter freigabe von insulin
BR0103033A (pt)	2002-03-05	Partìculas farmacêuticas de sabor mascarado
HUP0003323A2 (hu)	2001-06-28	Vorikonazolt tartalmazó gyógyászati készítmények
BR0010485A (pt)	2002-08-20	Formulações de derivados de eritromicina de liberação prolongada
IL84167A0 (en)	1988-03-31	Compositions containing bioactive materials adapted for oral administration and methods for administration thereof
BR9908438A (pt)	2000-10-31	Tabletes de desintegração rápida
CA2337885A1 (en)	2000-01-27	Enteric coated pharmaceutical tablet and method of manufacturing
Ain et al.	2002	Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug (s)
ATE253354T1 (de)	2003-11-15	Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
Trivedi et al.	2017	Colon targeted delivery system (CODES TM): Propitious approach in targeting colon
ATE238797T1 (de)	2003-05-15	Piroxicam enthaltende gastrointestinale zubereitung aus merheren einheiten bestehend
EP0761209A3 (de)	1998-02-04	Ranitidinformulierungen mit gesteuerter Freisetzung
WO2004108792A3 (en)	2005-03-24	Novel biodegradable aliphatic polyesters and pharmaceutical compositions and applications thereof